Dxs International Plc · AQUIS:DXSP
Dxs International — FY2025 Earnings Presentation
13 slides from Dxs International's earnings presentation, November 2025
Slide 1: Annual Report Year Ended April 2025
November 2025 ANNUAL REPORT © © Year Ended April 2025 COMPANY NO 6311313
Slide 2: Results for Year End April 2025
Turnover up by 5% to £3,469,917. Loss of £94,750 – largely due to a combination of on-going development and reduced tax credits due to HMRC policy changes – down by £132,566. RESULTS FOR YEAR END APRIL 2025 2
Slide 3: SMART Referrals Highlights for the Year
Almost 2 million referrals (17% of total annual GP referrals in England) continue to get sent via our SMART Referral solution SMART Referrals continue to deliver results – cutting down referral rejections and reducing waiting lists – both NHS priorities. Next-Gen - The new referral technology
Slide 4: What This Could Mean
A 27% price increase could enhance existing referral income by £440,000 p.a. Existing customers bringing non referral practices on board could potentially increase annual revenue by more than £700,000 over 24 months. Some greenfield customers could generate another £1,000,000 over the next 30
Slide 5: Secondary Care Highlights for the Year
Secondary Care - Our SMART Referral solution, customised for each specialty unit, continues to reduce referral rejections and patient waiting times. Building on this success, DXS is piloting new functionality that automatically populates specialty unit systems with referral data - eliminating ma
Slide 6: ExpertCare Highlights for the Year
Medicine Optimisation – Our ExpertCare solution recently completed an Innovate UK funded 18-month evaluation. The formal evaluation, conducted by the York Health Economics Consortium (YHEC) and concluded in July 2025, demonstrated an excellent return on investment for the NHS in the management o
Slide 7: Medicine Information
DXS Continues to provide a channel to the pharmaceutical industry enabling pharma organisations to provide information to GPs in their workflow and during the patient consultation. This revenue stream has remained fairly robust and new opportunities will emerge for pharma with the development of
Slide 8: What Our Users Say
«+. Generally speaking the ease with which | can search for word, find the form, fill in the relevant bits along with the autopopulation, land then save/email it off immediately is really satistying.It| think ‘about where we were with our referral processes and access to lpathways across primary car
Slide 9: The Future Roadmap
Partnering with a development house to build a suite of SMART Pathways. This initiative aligns with the NHS strategy of standardising pathways to ensure continuity and reduce variation in care. DXS awarded a bronze medal in a US competition entered by Jonathan Lewis on behalf of DXS. From DXS’s
Slide 10: Summary
The NHS continues to face significant pressure to reduce waiting times and address the growing challenge of CVD. Within its Ten-Year Digital Transformation Plan, the NHS has identified digital innovation and preventive care as key priorities, with targeted funding directed toward high-impact, tech
Slide 11: Income Statement Year Ended April 2025
Income Statement Year Ended April 2025 2025 2024 Continuing Continuing Operations Operations £ £ Turnover 3,469,917 3,308,359 Cost of sales (479,382) (428,212) Gross Profit 2,990,535 2,880,147 Grant income 132,993 136,570 Administration costs (3,251,011) (2,494,510) Depreciation, amortisation and im
Slide 12: Statement of Financial Position As at 30 April 2025
Statement of Financial Position As at 30 April 2025 Group Group Company Company 2025 2024 2025 2024 Fixed assets £ £ £ £ Intangible assets 1,455,000 1,455,000 - - Tangible assets - 1,038 - - Investments ________- _________- 535,768 507,954 1,455,000 1,456,038 535,768 507,954 Current assets Debtors:
Slide 13: Thank You
THANK YOU 13